| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7e84469887e6a49345b27bbd275c15f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7f04f6fd83c75aa5835ad6b4c4d089ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_efb1fce5b478ae9182b01308e87942e3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5152
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18871
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-552
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18834 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-155 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-155 |
| filingDate |
2012-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b412975c7e5060a6085cdc122ccbd1da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97be69295351b57ff168f3bbfdbf46ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b70851cd41739da3668735681a3e33e |
| publicationDate |
2014-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2519763-C1 |
| titleOfInvention |
Method for immune therapy of oncological diseases and pharmaceutical compositions of sendai virus of cancer |
| abstract |
FIELD: medicine. n SUBSTANCE: composition containing an isolated native biologically active Sendai virus strain deposited in the American Type Culture Collection (ATCC) No. PTA-13024, and a pharmaceutically acceptable carrier, is administered into a patient. A group of inventions also refers to a pharmaceutical composition containing the isolated, genetically engineered, biologically active Sendai virus strain prepared on the basis of a viral material deposited in the American Type Culture Collection (ATCC) No. PTA-13024. n EFFECT: higher clinical effectiveness in treating oncological diseases ensured by the oncolytic action of Sendai virus and the viral stimulation of the antitumour immunity. n 21 cl, 1 dwg, 8 ex |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2662916-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2695136-C1 |
| priorityDate |
2012-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |